Literature DB >> 10334225

Prevalence of Meniere disease in Finland.

J Kotimäki1, M Sorri, E Aantaa, J Nuutinen.   

Abstract

OBJECTIVES: To assess the prevalence of Meniere disease in the population of 5 million in Finland according to the criteria of the Committee on Hearing and Equilibrium of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) recommendation. STUDY
DESIGN: Retrospective investigation based on patient records of 306 patients treated for Meniere disease and recognized as such according to the International Statistical Classification of Diseases and Related Health Problems (ICD-9 or ICD-10) in seven Finnish hospitals serving a population of 1.5 million people.
METHODS: Patients were selected from the computerized patient registers of outpatients and inpatients having received an appropriate diagnosis during the period from 1992 to 1996 and re-evaluated. Definite cases according to AAO-HNS guidelines were identified to calculate the prevalence of Meniere disease in Finland at the end of 1996.
RESULTS: A total of 131 definite cases of Meniere disease were identified. The prevalence of at least 43 per 100,000 and an average annual incidence of 4.3 per 100,000 were obtained. The prevalence turned out to be higher (P<.001) in Northern areas (49/100,000) than in the south (38/100,000). The prevalence did not differ in the areas of university hospitals (44/100,000) from those of central hospitals (42/100,000).
CONCLUSIONS: The prevalence and incidence in Finland is lower than could be expected from previous international surveys, most of which provide inadequate data for forming a real picture of the epidemiology of Meniere disease. Uniform diagnostic criteria are indispensable for further research.

Entities:  

Mesh:

Year:  1999        PMID: 10334225     DOI: 10.1097/00005537-199905000-00013

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  13 in total

1.  Meniere's disease: Still a mystery disease with difficult differential diagnosis.

Authors:  A Vassiliou; P V Vlastarakos; P Maragoudakis; D Candiloros; T P Nikolopoulos
Journal:  Ann Indian Acad Neurol       Date:  2011-01       Impact factor: 1.383

2.  Identification of early-stage Meniere's disease as a cause of unilateral tinnitus.

Authors:  Haider Alsarhan
Journal:  J Otol       Date:  2020-11-11

3.  The Polymorphic Analysis of the Human Potassium Channel KCNE Gene Family in Meniere's Disease-A Preliminary Study.

Authors:  Qingqing Dai; Dan Wang; Hong Zheng
Journal:  J Int Adv Otol       Date:  2019-04       Impact factor: 1.017

Review 4.  [Epidemiology of dizziness and vertigo].

Authors:  H K Neuhauser
Journal:  Nervenarzt       Date:  2009-08       Impact factor: 1.214

5.  Vestibular function and vertigo control after intratympanic gentamicin for Ménière's disease.

Authors:  Kimanh D Nguyen; Lloyd B Minor; Charles C Della Santina; John P Carey
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

6.  Tinnitus and Ménière's disease: characteristics and prognosis in a tinnitus clinic sample.

Authors:  C Herraiz; M C Tapia; G Plaza
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-03-24       Impact factor: 2.503

7.  Menière's disease treated by grommet insertion.

Authors:  R G Kanegaonkar; A Najuko-Mafemera; R Hone; T Tikka
Journal:  Ann R Coll Surg Engl       Date:  2019-09-11       Impact factor: 1.891

Review 8.  The aetiopathologies of Ménière's disease: a contemporary review.

Authors:  B S Oberman; V A Patel; S Cureoglu; H Isildak
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-08       Impact factor: 2.124

Review 9.  Towards personalized medicine in Ménière's disease.

Authors:  Jose Antonio Lopez-Escamez; Angel Batuecas-Caletrio; Alexandre Bisdorff
Journal:  F1000Res       Date:  2018-08-15

10.  Betahistine in the treatment of Ménière's disease.

Authors:  Michel Lacour; Paul H van de Heyning; Miroslav Novotny; Brahim Tighilet
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.